Barclays Maintains Equal-Weight on Minimed Group, Lowers Price Target to $20
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Barclays analyst Christopher Pasquale maintains Minimed Group (NASDAQ:MMED) with a Equal-Weight and lowers the price target from $22 to $20.
Barclays analyst Christopher Pasquale maintains Minimed Group (NASDAQ:MMED) with a Equal-Weight and lowers the price target from $22 to $20.
